Repurposing drugs in endometrial cancer using genomic variants database

Bibliographic Details
Title: Repurposing drugs in endometrial cancer using genomic variants database
Authors: Darmawi, Donel S, Wiwin Suhandri, Wirawan Adikusuma, Lalu Muhammad Irham, Winarto, Renardy Reza Razali, Wiwit Ade Fidiawati, Auren Nathania, Leina Putri Zahra
Source: Pharmaciana, Vol 13, Iss 3, Pp 306-316 (2023)
Publisher Information: Universitas Ahmad Dahlan, 2023.
Publication Year: 2023
Collection: LCC:Pharmacy and materia medica
Subject Terms: acitretin, bosutinib, drug reporpusing, endometrial cancer, genomics variants, nilutamide, Pharmacy and materia medica, RS1-441
More Details: Globally, endometrial cancer (EC) is the six most common cancers related to female reproductive. EC incidence and mortality rates have increased over the last decade. Cytotoxic therapy with carboplatin or paclitaxel is the recommended first-line treatment for EC patients. However, the options for following therapy are limited. The latest advances in molecular studies have uncovered the nature of genetic alterations in EC, compelling methods for further research into the treatment of EC since they may disclose to tailored pharmacological therapy. The aim of this study was to identify novel drug candidates in treating EC using genomics variants and biological pathway. The genomic variants of EC were downloaded from cBioportal database. We established connection between the biological EC risk genes from cBioportal database and the DrugBank database. Finally, we used Connectivity Map (CMap) analysis to identify possible drugs whose mechanisms coincided with therapeutic targets and rank them in accordance to scoring criteria. We identified novel conceivable candidate drugs for EC, they are Bosutinib, Acitretin and Nilutamide. These drugs exhibit robust scores in the CMap analysis compare to paclitaxel. We also discovered BCR-ABL1 and AR as potential biomarker-driven therapy in EC. This study demonstrates the possibility of using genetic network analysis combined with bioinformatics to repurpose drugs for the treatment of EC. Further investigation will be undertaken to explore the mechanisms involved in the application of BCR-ABL1 and AR for treating of EC.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2088-4559
2477-0256
Relation: http://journal.uad.ac.id/index.php/PHARMACIANA/article/view/27201/pdf_287; https://doaj.org/toc/2088-4559; https://doaj.org/toc/2477-0256
DOI: 10.12928/pharmaciana.v13i3.27201
Access URL: https://doaj.org/article/25df09b0972e491a8573a6282f09f295
Accession Number: edsdoj.25df09b0972e491a8573a6282f09f295
Database: Directory of Open Access Journals
More Details
ISSN:20884559
24770256
DOI:10.12928/pharmaciana.v13i3.27201
Published in:Pharmaciana
Language:English